January 15, 2021

To whom it may concern:

Company Name TOHO HOLDINGS CO., LTD.
Corporate Representative Atsushi Udoh, President and Representative Director
Contact: Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department

Announcement of Capital and Business Alliance with KUBIX Inc.

TOHO HOLDINGS CO., LTD. (Head Office: Tokyo; President and Representative Director: Atsushi Udoh; hereinafter "TOHO HOLDINGS") is pleased to announce that it has invested in and established a business alliance with KUBIX Inc., a medical venture company (Head Office: Ishikawa; CEO: Hiroshi Tanno; hereinafter "KUBIX"), regarding exclusive distribution as described below.

1. Reason for capital and business alliance

TOHO HOLDINGS is a corporate group active in medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan "Total Commitment to Good Health". TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

KUBIX was established in August 2004 as a medical venture company originating at Kanazawa University. In addition to providing contract testing services to determine the presence or absence of gastrointestinal cancer by analyzing RNA expression from blood in cooperation with more than 1,300 medical institutions across Japan, KUBIX also develops, manufactures and sells research kits such as PCR reagents for the detection of COVID-19 and quantification of HBV.

In respectful recognition of KUBIX’s business activities, TOHO HOLDINGS has made this investment to support the research and development being promoted by KUBIX, and obtains exclusive rights to distribute products to be developed by KUBIX.

2. Overview of KUBIX

(1) Company name: KUBIX Inc.
(2) Location: h6-1 Netsuno, Hakusan, Ishikawa.
(3) Representative: Hiroshi Tanno, CEO
(4) Established: August 2004
(5) Business content: Contract analysis services, manufacturing and sales of in vitro diagnostics, etc.
(6) Capital: 172,197,000 yen
(7) Fiscal year end: September 30
(8) Number of employees: 18

3. Performance outlook

Impact to consolidated performance is minor.